Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Molina-Collada Juan, Plasencia-Rodriguez Chamaida, García-García Verónica, Del Bosque Iván, Pavía-Pascual Marina, Villapún Burgoa Beatriz, Bourgeois-Avella Camille, Roig-Kim Montserrat, Narváez Javier, Hernández-Rodríguez Isabel, Saez Juan Carlos, Almeida Cristina, García-Dorta Alicia, Uriarte Itzazelaia Esther, Campos Daniel, Dos-Santos Raquel, Pérez-Pampín Eva, Jiménez Núñez Francisco Gabriel, Fernández-Fernández Elisa, Villalba Alejandro, Bou Núria, Pérez-García Carolina, Rusinovich Lovgach Olga, Martínez Rodado Alejandro, González Roxana, Cepas-Gutiérrez Francisco José, Olivas-Vergara Otto, Berrocal Minerva, Molina Nuria, González Mazón Iñigo, Toledano Esther, Tortosa-Cabañas Marina, Vellosillo González Perceval, González Navarro Pablo, Navarro-Compán Victoria, Carmona Loreto, ARCA project collaborative group
Аннотация
METHODS: The ARthritis and CAncer registry is a nationwide retrospective study, including patients with RA and prior cancer. Collected variables included RA characteristics, DMARDs received, cancer type and demographics. The primary outcome was the occurrence of new primary cancer, locoregional progression or metastasis during follow-up. Adjusted Cox regression models were used to estimate HRs for cancer events. Treatment strategies involving conventional synthetic (cs)DMARDs served as the reference for comparison.
RESULTS: Among 728 patients with RA, 80 cases of cancer were identified over a cumulative exposure period of 11 022 years, with an overall cancer incidence rate of 7.3 (95% CI 5.8 to 9.0) per 1000 person-years. Adjusted HRs for all cancers (95% CI) compared with csDMARDs were 0.94 (0.73 to 1.21) for tumour necrosis factor inhibitors, 1.03 (0.61 to 1.74) for IL6-inhibitors, 0.81 (0.46 to 1.42) for CD20 inhibitors, 0.6 (0.26 to 1.4) for targeted synthetic DMARDs and 0.74 (0.41 to 1.34) for cytotoxic T-lymphocyte-associated protein 4-analogue. No differences in cancer risk were observed after adjusting for duration of exposure, line of advanced therapy or prior cancer status.
CONCLUSION: This real-world data did not identify differences in the risk of new primary cancer, locoregional progression or metastasis across different DMARDs strategies in patients with RA and prior cancer.